Protective effects of spironolactone against anthracycline-induced cardiomyopathy

European Journal of Heart Failure

Volumn 17, Issue 1, 2015, Pages 81-89

  Akpek, Mahmut ^a   Ozdogru, Ibrahim ^a   Sahin, Omer ^a   Inanc, Mevlude ^a   Dogan, Ali ^a   Yazici, Cevat ^a   Berk, Veli ^a   Karaca, Halit ^a   Kalay, Nihat ^a   Oguzhan, Abdurrahman ^a   Ergin, Ali ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Anthracycline; Cardiomyopathy; Spironolactone

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; PLACEBO; SPIRONOLACTONE; TROPONIN I; ANTINEOPLASTIC ANTIBIOTIC; MINERALOCORTICOID ANTAGONIST;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH CARE; HEART PROTECTION; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE DOPPLER IMAGING; TWO DIMENSIONAL ECHOCARDIOGRAPHY; BREAST NEOPLASMS; CARDIOMYOPATHIES; CHEMICALLY INDUCED; ECHOCARDIOGRAPHY; ECHOGRAPHY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CARDIOMYOPATHIES; DOUBLE-BLIND METHOD; DOXORUBICIN; ECHOCARDIOGRAPHY; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84921419024     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.196     Document Type: Article

References (29)

1. Jones RB, Holland JF, Bhardwaj S, Norton L, Wilfinger C, Strashun A. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 1987;5:172-177.
2. Gregory SA, Trümper L. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann Oncol 2005;16:1413-1424.
3. Bleyer WA. The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990;40:355-367.
4. Gatta G, Capocaccia R, Coleman M.P, Ries L.A, Berrino F. Childhood cancer survival in Europe and the United States. Cancer 2002;95:1767-1772.
5. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
6. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, Canetta R, Castellani R, Villa E, Gallagher CG, von Melchner H, Hayat M, Ribaud P, De Wasch G, Mattsson W, Heinz R, Waldner R, Kolaric K, Buehner R, Ten Bokkel-Huyninck W, Perevodchikova NI, Manziuk LA, Senn HJ, Mayr AC. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979;63:827-834.
7. Erdoʇan D, Yücel H, Alanoʇlu EG, Uysal BA, Koçer M, Ozaydin M, Doʇan A. Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy? Turk Kardiyol Dern Ars 2011;39:646-653.
8. Solomon SD, Pfeffer MA. Aldosterone antagonism and myocardial infarction: from animals to man and back. J Am Coll Cardiol 2003;42:1674-1676.
9. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
10. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
11. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165-193.
12. Tuzgen S, Hanimoglu H, Tanriverdi T, Kacira T, Sanus GZ, Atukeren P, Dashti R, Gumustas K, Canbaz B, Kaynar MY. Relationship between DNA damage and total antioxidant capacity in patients with glioblastoma multiforme. Clin Oncol 2007;19:177-181.
13. Schimke I, Müller J, Priem F, Kruse I, Schön B, Stein J, Kunze R, Wallukat G, Hetzer R. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 2001;38:178-183.
14. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-2565.
15. Wei Y, Whaley-Connell AT, Habibi J, Rehmer J, Rehmer N, Patel K, Hayden M, DeMarco V, Ferrario CM, Ibdah JA, Sowers JR. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 2009;53:158-165.
16. Michea L, Villagrán A, Urzúa A, Kuntsmann S, Venegas P, Carrasco L, Gonzalez M, Marusic ET. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 2008;52:295-300.
17. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007;49:355-364.
18. Wang H, Shimosawa T, Matsui H, Kaneko T, Ogura S, Uetake Y, Takenaka K, Yatomi Y, Fujita T. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens 2008;26:1453-1462.
19. Cruet-Hennequart S, Prendergast ÁM, Shaw G, Barry FP, Carty MP. Doxorubicin induces the DNA damage response in cultured human mesenchymal stem cells. Int J Hematol 2012;96:649-656.
20. Sinha BK, Trush MA, Kennedy KA, Mimnaugh EG. Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res 1984;44:2892-2896.
21. Philips ES, Gilladoga A, Marquardt H. Some observations on the toxicity of adriamycin (NSC123127). Cancer Chemother Rep 1975;6:177-181.
22. Breed JGS, Zimmerman ANB, Dormans JAMA, Pinedo HM. Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. Cancer Res 1980;40:2033-2038.
23. Legha SS, Wang YM, Mackay B, Ewer M, Hortobagyi GN, Benjamin RS, Ali MK. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann NY Acad Sci 1982;393:411-418.
24. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-2262.
25. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, Kalay N, Dikilitas M, Yarlioglues M, Karaca H, Berk V, Ardic I, Ergin A, Lam YY. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 2013;167:2306-2310.
26. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009;60:373-381.
27. Iqbal M, Dubey K, Anwer T, Ashish A, Pillai KK. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 2008;60:382-390.
28. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:560-571.
29. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.